These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35279508)

  • 1. Patient-reported outcomes one year after positive sentinel lymph node biopsy with or without axillary lymph node dissection in the randomized SENOMAC trial.
    Appelgren M; Sackey H; Wengström Y; Johansson K; Ahlgren J; Andersson Y; Bergkvist L; Frisell J; Lundstedt D; Rydén L; Sund M; Alkner S; Vrou Offersen B; Filtenborg Tvedskov T; Christiansen P; de Boniface J;
    Breast; 2022 Jun; 63():16-23. PubMed ID: 35279508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial.
    de Boniface J; Appelgren M; Szulkin R; Alkner S; Andersson Y; Bergkvist L; Frisell J; Gentilini OD; Kontos M; Kühn T; Lundstedt D; Offersen BV; Olofsson Bagge R; Reimer T; Sund M; Christiansen P; Rydén L; Filtenborg Tvedskov T;
    Lancet Oncol; 2024 Sep; 25(9):1222-1230. PubMed ID: 39121881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The generalisability of randomised clinical trials: an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer.
    de Boniface J; Ahlgren J; Andersson Y; Bergkvist L; Frisell J; Lundstedt D; Olofsson Bagge R; Rydén L; Sund M;
    Breast Cancer Res Treat; 2020 Feb; 180(1):167-176. PubMed ID: 31989379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial.
    de Boniface J; Frisell J; Andersson Y; Bergkvist L; Ahlgren J; Rydén L; Olofsson Bagge R; Sund M; Johansson H; Lundstedt D;
    BMC Cancer; 2017 May; 17(1):379. PubMed ID: 28549453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment.
    Tinterri C; Canavese G; Gatzemeier W; Barbieri E; Bottini A; Sagona A; Caraceni G; Testori A; Di Maria Grimaldi S; Dani C; Boni L; Bruzzi P; Fernandes B; Scorsetti M; Zambelli A; Gentile D;
    Br J Surg; 2023 Aug; 110(9):1143-1152. PubMed ID: 37471574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A patient- and assessor-blinded randomized controlled trial of axillary reverse mapping (ARM) in patients with early breast cancer.
    Beek MA; Gobardhan PD; Klompenhouwer EG; Menke-Pluijmers MB; Steenvoorde P; Merkus JW; Rutten HJ; Voogd AC; Luiten EJ
    Eur J Surg Oncol; 2020 Jan; 46(1):59-64. PubMed ID: 31402072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases.
    de Boniface J; Filtenborg Tvedskov T; Rydén L; Szulkin R; Reimer T; Kühn T; Kontos M; Gentilini OD; Olofsson Bagge R; Sund M; Lundstedt D; Appelgren M; Ahlgren J; Norenstedt S; Celebioglu F; Sackey H; Scheel Andersen I; Hoyer U; Nyman PF; Vikhe Patil E; Wieslander E; Dahl Nissen H; Alkner S; Andersson Y; Offersen BV; Bergkvist L; Frisell J; Christiansen P; ;
    N Engl J Med; 2024 Apr; 390(13):1163-1175. PubMed ID: 38598571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of the Axilla in T1-2 Breast Cancer Patients with Macrometastatic Sentinel Node Involvement Who Underwent Breast-Conserving Therapy.
    Kuru B; Yuruker S; Sullu Y; Gursel B; Ozen N
    J Invest Surg; 2019 Jan; 32(1):48-54. PubMed ID: 28945489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axillary lymph node dissection vs. sentinel node biopsy for early-stage clinically node-negative breast cancer: a systematic review and meta-analysis.
    Petousis S; Christidis P; Margioula-Siarkou C; Liberis A; Vavoulidis E; Margioula-Siarkou G; Vatopoulou A; Papanikolaou A; Mavromatidis G; Dinas K
    Arch Gynecol Obstet; 2022 Oct; 306(4):1221-1234. PubMed ID: 35249123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial.
    Zavagno G; De Salvo GL; Scalco G; Bozza F; Barutta L; Del Bianco P; Renier M; Racano C; Carraro P; Nitti D;
    Ann Surg; 2008 Feb; 247(2):207-13. PubMed ID: 18216523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in axillary treatment for breast cancer patients undergoing sentinel lymph node biopsy as determined by a questionnaire from the Japanese Breast Cancer Society.
    Imoto S; Yamauchi C; Komoike Y; Tsugawa K; Yotsumoto D; Wada N; Ueno T; Oba MS; Shien T; Sugae S; Tsuda H; Yoneyama K
    Breast Cancer; 2017 May; 24(3):427-432. PubMed ID: 27553957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of modern-day axillary treatment on patient reported arm morbidity and physical functioning in breast cancer patients.
    Gregorowitsch ML; Verkooijen HM; Houweling A; Fuhler N; Koelemij R; Schoenmaeckers EJP; Sier MF; Ernst MF; Witkamp AJ; Van Dalen T; Young-Afat DA; van den Bongard DHJG;
    Radiother Oncol; 2019 Feb; 131():221-228. PubMed ID: 30033384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
    Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
    JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of quality of life and arm complaints after axillary lymph node dissection vs sentinel lymph node biopsy in breast cancer patients.
    Peintinger F; Reitsamer R; Stranzl H; Ralph G
    Br J Cancer; 2003 Aug; 89(4):648-52. PubMed ID: 12915872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does the presence of sentinel lymph node macrometastases in breast cancer patients require axillary lymph node dissection?-Single-center analysis.
    Nowikiewicz T; Zegarski W; Pagacz K; Nowacki M; Morawiec-Sztandera A; Głowacka-Mrotek I; Sowa M; Biedka M; Kołacińska A
    Breast J; 2018 Sep; 24(5):724-729. PubMed ID: 29476570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial.
    Henke G; Knauer M; Ribi K; Hayoz S; Gérard MA; Ruhstaller T; Zwahlen DR; Muenst S; Ackerknecht M; Hawle H; Fitzal F; Gnant M; Mátrai Z; Ballardini B; Gyr A; Kurzeder C; Weber WP
    Trials; 2018 Dec; 19(1):667. PubMed ID: 30514362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
    Boughey JC; Suman VJ; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Kuerer HM; Bowling M; Flippo-Morton TS; Byrd DR; Ollila DW; Julian TB; McLaughlin SA; McCall L; Symmans WF; Le-Petross HT; Haffty BG; Buchholz TA; Nelson H; Hunt KK;
    JAMA; 2013 Oct; 310(14):1455-61. PubMed ID: 24101169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conservative axillary surgery is emerging in the surgical management of breast cancer.
    Noguchi M; Inokuchi M; Yokoi-Noguchi M; Morioka E; Haba Y
    Breast Cancer; 2023 Jan; 30(1):14-22. PubMed ID: 36342647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.
    Classe JM; Loaec C; Gimbergues P; Alran S; de Lara CT; Dupre PF; Rouzier R; Faure C; Paillocher N; Chauvet MP; Houvenaeghel G; Gutowski M; De Blay P; Verhaeghe JL; Barranger E; Lefebvre C; Ngo C; Ferron G; Palpacuer C; Campion L
    Breast Cancer Res Treat; 2019 Jan; 173(2):343-352. PubMed ID: 30343457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morbidity in breast cancer patients with sentinel node metastases undergoing delayed axillary lymph node dissection (ALND) compared with immediate ALND.
    Goyal A; Newcombe RG; Chhabra A; Mansel RE
    Ann Surg Oncol; 2008 Jan; 15(1):262-7. PubMed ID: 17879117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.